High Sensitivity of Biocept's Target Selector Blood-Based Liquid Biopsy Tests Featured in Two Abstracts at ASCO
- The first abstract, "The performance of a comprehensive CTC anti-body capture cocktail in the detection and phenotypic analysis of CTCs," provides further clinical validation of
Biocept's proprietary technology to detect a wide range of CTCs including both epithelial (tissues that line the cavities and surfaces of blood vessels and organs) and non-epithelial, as well as those undergoing epithelial mesenchymal transformation (EMT). Compared to traditional methods of CTC isolation and detection,Biocept's multiplexed antibody cocktail method improves the capture and characterization of a broader range of CTC phenotypes resulting in a more thorough screen for predictive and prognostic tumor markers, thereby enabling an informed treatment strategy. - The second abstract, "ctDNA assay to detect EGFR mutations and mechanisms of resistance to EGFR tyrosine kinase inhibitors," provides additional support for the high level of sensitivity and high level of concordance ( > 80%) of
Biocept's ctDNA assay compared to tissue results. The data cited in the abstract are from a study being conducted withLyudmila Bazhenova , MD, at theUniversity of California San Diego .
"These study data further support the use of our Target Selector blood-based tests for sensitive real-time monitoring and potential early identification of biomarkers that could be beneficial in assessing disease progression and treatment response," stated
"The data from
About
Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this release are not strictly historical, including without limitation statements as to our ability to improve the diagnosis and treatment of cancer, our ability to build additional
support for the clinical utility of our liquid biopsy offerings, our ability to demonstrate the utility of our liquid biopsy diagnostic assays to profile and monitor a patient's cancer and biomarker status to assess treatment response over time, the ability of our tests to be beneficial in assessing disease progression and treatment response, our impact on diagnostic strategies and planned future offerings, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our
Logo - http://photos.prnewswire.com/prnh/20151013/276540LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/high-sensitivity-of-biocepts-target-selector-blood-based-liquid-biopsy-tests-featured-in-two-abstracts-at-asco-300274491.html
SOURCE
News Provided by Acquire Media